Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.03
(
-0.63%
)
US TECH 100
25,767.20
(
-0.40%
)
Dow Jones
49,149.85
(
-0.60%
)
Brent Oil
94.88
(
4.64%
)
Bitcoin
75,560.91
(
-0.44%
)
News Focus
News Focus
Post# of 80490
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: Whosetosay post# 74200

Sunday, 06/26/2016 12:06:52 PM

Sunday, June 26, 2016 12:06:52 PM

Post# of 80490
The problem is ponatinib is not going to extract much value either way at the moment, see how much INCY paid for EU operation and rights where CML market size isn't much different from US. Obviously INCY was more interested in EU operation rather than ponatinib, otherwise they would have agreed to pay much higher portion of OPTIC-2L trial expense because it is a completely outside of US trial.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today